## SHARED CARE AGREEMENT

<table>
<thead>
<tr>
<th>Name of medicine</th>
<th>Name (brand)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Indication</td>
<td>...</td>
</tr>
</tbody>
</table>

Version: 1.0  Approval date: mmm yyyy  Review date: mmm yyyy

The Shared Care Agreement (SCA) is intended to facilitate the accessibility and safe prescribing of complex treatments across the secondary/primary care interface. It does not contain all of the relevant product information, which should be sought using the current British National Formulary and manufacturer’s Summary of Product Characteristics. The SCA must be used in conjunction with the NHS Lothian Policy and Procedures for the Shared Care of Medicines, available at: [http://www.ljf.scot.nhs.uk/SharedCareofMedicines/Pages/default.aspx](http://www.ljf.scot.nhs.uk/SharedCareofMedicines/Pages/default.aspx)

### Roles and responsibilities

List below specific responsibilities that are additional to those detailed in the policy

Listed below are specific responsibilities that are additional to those included in the NHS Lothian Policy and Procedures for Shared Care. Please refer to the policy for core roles and responsibilities that apply to all Shared Care Agreements.

**Consultant**

Please give specific information where this will be helpful to the primary care prescribers, e.g.

- Initiation of therapy with ‘drug x’ over a one month period, then supply of the medicine for one further month once the patient’s treatment is stable
- Patient monitoring – 3 monthly for the first 12 months, then 6 monthly in the longer term

**General Practitioner**

- 
- 

**Patient, relatives, carers**

*If there are no specific responsibilities that are additional to those included in the NHS Lothian Policy and Procedures for Shared Care, please include the statement ‘As listed in NHS Lothian Policy and Procedures for the Shared Care of Medicines’*

**Support and Advice for the GP**

*E.g. Contact points, telephone numbers, supportive guidance*

**Key Information on the Medicine**


**Background to disease and use of drug for the given indication**

*Brief paragraph*

**Indication**

*Specific to approved use in NHS Lothian (check formulary status)*
Dosage and administration
Include only where no SPC is available, i.e. for unlicensed /off-label use, and in line with approved use in NHS Lothian

Monitoring

<table>
<thead>
<tr>
<th>Test</th>
<th>Frequency</th>
<th>Abnormal Result</th>
<th>Action if Abnormal Result</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Cautions, contraindications - Refer to current Summary of Product Characteristics (SPC): www.medicines.org.uk
Include only where no SPC is available, i.e. for unlicensed /off-label use, and in line with approved use in NHS Lothian

Adverse effects - Refer to current Summary of Product Characteristics (SPC): www.medicines.org.uk
Include only where no SPC is available, i.e. for unlicensed /off-label use, and in line with approved use in NHS Lothian, or if there is specific local advice on action to be taken if a particular adverse effect arises

Drug interactions - Refer to current Summary of Product Characteristics (SPC): www.medicines.org.uk
Include only where no SPC is available, i.e. for unlicensed /off-label use, and in line with approved use in NHS Lothian

Approved for use by the Shared Care Agreement Review Group – relevant date